/
Rare Disease
Fabry Disease
12
Pipeline Programs↗
26
Active Trials↗
16
Companies Involved↗
Fabry Disease is an emerging landscape with 12 programs across 16 companies. The most active players are Chiesi Farmaceutici S.p.A., Idorsia Pharmaceuticals Ltd., Amicus Therapeutics. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 23
Phase 36
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
9 of 10 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
88
clinical trials
Completed43 · 49%
Recruiting17 · 19%
Terminated6 · 7%
Active, not recruiting6 · 7%
Unknown status6 · 7%
Withdrawn3 · 3%
Other7 · 8%
Clinical Trials
Trial Activity
88 trials
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)